Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Matuzumab · 1 trial · 2 indications
Objective response was defined as having a complete response (CR) or a partial response (PR). Response assessment was performed using modified World Health Organization (WHO) criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: greater than (\>) 50 percent (%) decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion.
| Arm | Type | Description |
|---|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | EXPERIMENTAL | - |
| ECX Only | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Matuzumab | DRUG | Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn. |
| Epirubicin | DRUG | Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles. |
| Cisplatin | DRUG | Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles. |
| Capecitabine | DRUG | Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles. |
Inclusion Criteria: * Histologically confirmed gastric adenocarcinoma or adenocarcinoma of the lower third of the esophagus * Metastatic disease * Immunohistological evidence of Epidermal Growth Factor Receptor (EGFR) expression from archived tissues * Eastern Cooperative Oncology Group Performance...
Top 20 of 37 competitors
Matuzumab is an investigational drug being studied for the treatment of esophageal cancer and gastric cancer. It is currently in Phase 2 clinical development and is being evaluated in combination with chemotherapy for these indications.
Matuzumab is being developed by Merck KGaA, a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with esophageal and gastric cancer.
Matuzumab is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial has been completed to assess its effects in combination with chemotherapy for esophago-gastric cancer.
Matuzumab has been studied in a completed Phase 2 clinical trial with the identifier NCT00215644. This trial evaluated matuzumab in combination with epirubicin, cisplatin, and capecitabine in patients with esophago-gastric cancer, enrolling 72 participants across Germany, Spain, Switzerland, and the United Kingdom.
Yes, Matuzumab is a small molecule drug. It is being investigated as a therapeutic option for esophageal and gastric cancer, and its clinical development is focused on oncology applications.